Cit-PAB-OH is widely used in the development of antibody-drug conjugates (ADCs), which are targeted cancer therapies. It serves as a linker molecule, connecting the cytotoxic drug to the antibody. This linkage ensures that the drug is delivered specifically to cancer cells, minimizing damage to healthy tissues. The compound's stability in the bloodstream and its ability to release the drug efficiently at the target site make it a crucial component in enhancing the efficacy and safety of ADCs. Its application is pivotal in advancing precision medicine for treating various cancers.